Outourcing-Pharma focus on: FDA clinical trial initiatives

FDA signals new clinical trials flexibility

By Kirsty Barnes

- Last updated on GMT

The US Food and Drug Administration (FDA) has signalled it will
soon allow a new "adaptive" approach to clinical trials in order to
streamline drug testing and speed drugs to market.

The changes are designed to help the pharmaceutical industry save millions of dollars in drug development costs - which are currently skyrocketing - by saving time, preventing the number of study failures, and reducing the number of study participants required by over 30 per cent.

Currently patients and doctors involved in drug trials are not permitted to know the results of the trial until it is complete.

However, under new guidelines currently being prepared by the FDA, clinical trial sponsors will have the flexibility to examine early results of a trial half way through and modify the trial design in order to improve the chances of a positive result, or cancel the study if it appears ineffective.

"These new approaches to clinical trials can result in trial designs that tell us more about safety and benefits of drugs, in potentially shorter time frames, exposing fewer people to experimental treatments,"​ said Dr Scott Gottlieb, deputy FDA commissioner for medical and scientific affairs.

However, the current guidelines were put in place to prevent any bias that could affect the outcome of a study and critics in the industry believe the adaptive approach could cause the integrity of trials to be jeopardised.

Acknowledging the concerns, Gottlieb said that adaptive designs could lead to "complicated decisions and uncertainty about the best approach for data analysis."

"It may also be true that making decisions during a trial's course can increase the rate of making an erroneous decision,"​ he said.

The FDA said it plans to address these concerns and will be participating in a two day workshop in November to "discuss all of the many issues around adaptive designs."

It is also planning to empower the data safety monitoring board or a similar expert panel to conduct an interim look at results and make decisions about how best to adapt a trial.

"We also hope to have additional public meetings to help us with the development of these guidances and are open to new scientific advances in clinical trial design that enable us to learn more about how to safely guide clinical decisions,"​ said Gottlieb.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers